Go Pro
→ Trump’s $250 Bill – See Immediately (From Stansberry Research) (Ad)tc pixel Free RGNX Stock Alerts

REGENXBIO (RGNX) Financials

REGENXBIO logo
$11.20 -1.07 (-8.72%)
Closing price 04:00 PM Eastern
Extended Trading
$9.59 -1.61 (-14.40%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for REGENXBIO

Annual Income Statements for REGENXBIO

This table shows REGENXBIO's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -24 -63 -73 100 -95 -111 128 -280 -263 -227 -194
Consolidated Net Income / (Loss)		 -23 -63 -73 100 -95 -111 128 -280 -263 -227 -194
Net Income / (Loss) Continuing Operations		 -23 -63 -73 100 -95 -111 128 -280 -263 -227 -194
Total Pre-Tax Income 		-23 -63 -73 104 -97 -106 141 -280 -264 -227 -194
Total Operating Income		 -23 -65 -76 88 -149 -119 160 -263 -268 -233 -161
Total Gross Profit		 6.09 3.63 8.68 209 27 111 421 58 53 88 170
Total Revenue		 7.59 4.59 10 219 35 155 470 113 90 83 170
Operating Revenue		 7.33 4.59 10 219 35 155 470 113 90 83 170
Total Cost of Revenue		 1.50 0.96 1.71 9.68 8.24 43 49 55 37 -5.00 0.00
Other Cost of Revenue		 - - - 0.04 - 7.68 -2.57 0.00 0.00 -5.00 0.00
Total Operating Expenses		 29 69 85 121 176 230 261 321 321 322 332
Selling, General & Admin Expense		 12 24 27 37 52 64 79 85 88 77 83
Research & Development Expense		 17 45 57 84 124 166 181 242 232 209 228
Other Operating Expenses / (Income)		 0.03 -0.10 0.12 - -0.01 0.30 0.33 -6.68 0.40 34 20
Impairment Charge		 - - - - - - - 0.00 0.00 2.10 0.00
Total Other Income / (Expense), net		 0.33 1.94 2.72 16 52 13 -19 -18 4.48 6.24 -33
Interest Expense		 0.02 - - 0.00 0.00 0.77 26 23 6.86 13 45
Interest & Investment Income		 0.35 1.94 2.72 7.07 49 9.72 6.83 5.38 11 19 12
Other Income / (Expense), net		 - - - 8.95 2.95 4.27 0.72 0.34 0.03 0.17 0.08
Basic Earnings per Share		 ($2.59) ($2.38) ($2.45) $2.99 ($2.58) ($2.98) $3.01 ($6.50) ($6.02) ($4.59) ($3.76)
Weighted Average Basic Shares Outstanding		 9.17M 26.41M 29.88M 33.43M 36.69M 37.28M 42.44M 43.15M 43.73M 49.51M 51.57M
Diluted Earnings per Share		 ($2.59) ($2.38) ($2.45) $2.73 ($2.58) ($2.98) $2.91 ($6.50) ($6.02) ($4.59) ($3.76)
Weighted Average Diluted Shares Outstanding		 9.17M 26.41M 29.88M 36.65M 36.69M 37.28M 43.91M 43.15M 43.73M 49.51M 51.57M
Weighted Average Basic & Diluted Shares Outstanding		 9.17M 26.41M 29.90M 31.30M 37.14M 42.50M 42.95M 43.46M 44.43M 50.09M 51.61M

Quarterly Income Statements for REGENXBIO

This table shows REGENXBIO's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -62 -63 -63 -53 -60 -51 6.08 -71 -62 -67 -90
Consolidated Net Income / (Loss)		 -62 -63 -63 -53 -60 -51 6.08 -71 -62 -67 -90
Net Income / (Loss) Continuing Operations		 -62 -62 -63 -53 -60 -52 6.08 -71 -62 -67 -90
Total Pre-Tax Income 		-62 -63 -63 -53 -60 -51 6.08 -71 -62 -67 -90
Total Operating Income		 -65 -64 -64 -56 -62 -51 12 -63 -52 -58 -83
Total Gross Profit		 17 11 16 22 24 20 89 21 30 30 6.39
Total Revenue		 29 22 16 22 24 21 89 21 30 30 6.39
Operating Revenue		 29 22 16 22 24 21 89 21 30 30 6.39
Total Cost of Revenue		 12 11 0.00 0.00 0.00 1.32 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 81 75 79 78 86 71 77 85 82 88 90
Selling, General & Admin Expense		 23 19 18 19 19 20 20 20 20 22 21
Research & Development Expense		 58 56 55 49 54 50 53 60 56 60 57
Other Operating Expenses / (Income)		 0.22 0.12 4.25 11 12 0.83 3.45 5.25 5.79 5.98 11
Total Other Income / (Expense), net		 3.09 0.86 0.53 3.05 2.48 0.18 -6.04 -7.59 -9.53 -9.51 -6.69
Interest Expense		 1.62 1.36 1.97 0.45 0.82 9.42 8.57 11 13 12 8.71
Interest & Investment Income		 4.66 2.37 2.47 3.47 3.28 9.52 2.50 3.38 3.62 2.75 2.00
Other Income / (Expense), net		 0.06 -0.14 0.04 0.03 0.03 0.08 0.03 0.02 0.02 0.02 0.02
Basic Earnings per Share		 ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99) $0.12 ($1.38) ($1.20) ($1.30) ($1.72)
Weighted Average Basic Shares Outstanding		 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M 51.36M 51.48M 51.69M 51.57M 52.43M
Diluted Earnings per Share		 ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99) $0.12 ($1.38) ($1.20) ($1.30) ($1.72)
Weighted Average Diluted Shares Outstanding		 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M 51.43M 51.48M 51.69M 51.57M 52.43M
Weighted Average Basic & Diluted Shares Outstanding		 43.99M 44.43M 49.26M 49.42M 49.55M 50.09M 50.16M 50.51M 50.62M 51.61M 51.70M

Annual Cash Flow Statements for REGENXBIO

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 53 -29 22 30 -5.77 269 7.48 -248 -62 23 -23
Net Cash From Operating Activities		 -23 -49 -58 105 -108 -54 219 -207 -218 -173 -124
Net Cash From Continuing Operating Activities		 -23 -49 -58 105 -108 -54 219 -207 -218 -173 -124
Net Income / (Loss) Continuing Operations		 -23 -63 -73 100 -95 -111 128 -280 -263 -227 -194
Consolidated Net Income / (Loss)		 -23 -63 -73 100 -95 -111 128 -280 -263 -227 -194
Depreciation Expense		 0.08 0.54 2.69 3.98 7.15 8.41 9.56 13 17 16 16
Amortization Expense		 0.31 2.00 1.82 0.76 -1.20 1.08 5.84 4.71 0.69 -4.14 -5.48
Non-Cash Adjustments To Reconcile Net Income		 -0.82 6.51 9.78 7.75 -14 39 52 45 37 43 55
Changes in Operating Assets and Liabilities, net		 0.72 5.36 0.90 -7.77 -5.33 8.86 23 10 -10 -0.66 5.13
Net Cash From Investing Activities		 -164 19 -4.79 -279 94 123 -407 -12 191 103 -16
Net Cash From Continuing Investing Activities		 -164 19 -4.79 -279 94 123 -407 -12 191 103 -16
Purchase of Property, Plant & Equipment		 -0.52 -8.15 -7.16 -13 -12 -27 -84 -31 -9.96 -2.44 -2.41
Purchase of Investments		 -163 -45 -69 -446 -191 -123 -498 -185 -87 -190 -333
Sale and/or Maturity of Investments		 - 73 71 180 296 273 176 204 287 296 319
Net Cash From Financing Activities		 239 0.12 85 204 8.38 200 195 -29 -35 93 117
Net Cash From Continuing Financing Activities		 239 0.12 85 204 8.38 200 195 -29 -35 93 117
Issuance of Debt		 - - - - - - - - - 0.00 144
Issuance of Common Equity		 145 - 83 191 1.31 1.80 218 1.74 6.70 132 1.05
Other Financing Activities, net		 0.11 0.18 2.49 14 7.06 198 -23 -31 -42 -40 -29
Cash Interest Paid		 0.01 - - - - - - - - 6.56 32
Cash Income Taxes Paid		 - - - 3.44 0.90 -0.19 6.00 12 -0.14 -0.07 0.29

Quarterly Cash Flow Statements for REGENXBIO

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -16 -19 78 -55 -1.15 0.91 73 -51 -21 -24 -19
Net Cash From Operating Activities		 -49 -41 -55 -45 -41 -32 34 -49 -56 -52 -76
Net Cash From Continuing Operating Activities		 -49 -41 -55 -45 -41 -32 34 -49 -56 -52 -76
Net Income / (Loss) Continuing Operations		 -62 -63 -63 -53 -60 -51 6.08 -71 -62 -67 -90
Consolidated Net Income / (Loss)		 -62 -63 -63 -53 -60 -51 6.08 -71 -62 -67 -90
Depreciation Expense		 4.37 4.34 4.18 4.05 3.96 4.02 3.96 3.91 3.89 3.87 3.86
Amortization Expense		 -0.13 -0.24 -0.47 -1.24 -1.32 -1.12 -1.07 -1.36 -1.82 -1.23 -0.88
Non-Cash Adjustments To Reconcile Net Income		 8.63 8.69 12 8.22 9.91 4.55 7.67 11 20 16 14
Changes in Operating Assets and Liabilities, net		 -0.40 9.34 -7.64 -3.54 6.49 12 17 8.05 -16 -3.46 -3.21
Net Cash From Investing Activities		 39 34 13 -0.27 50 40 45 -140 42 38 71
Net Cash From Continuing Investing Activities		 39 34 13 -0.27 50 40 45 -140 42 38 71
Purchase of Property, Plant & Equipment		 -1.44 -1.13 -0.56 -0.47 -0.33 -1.08 -1.02 -0.39 -0.49 -0.51 -1.24
Purchase of Investments		 -18 -19 -55 -83 -36 -16 -19 -211 -40 -63 -9.84
Sale and/or Maturity of Investments		 58 54 69 83 87 58 65 71 82 101 82
Net Cash From Financing Activities		 -4.81 -12 121 -9.45 -11 -7.74 -5.79 139 -7.08 -9.58 -14
Net Cash From Continuing Financing Activities		 -4.81 -12 121 -9.45 -11 -7.74 -5.79 139 -7.08 -9.58 -14
Issuance of Common Equity		 6.12 - 132 - 0.25 - 0.31 - 0.74 - 0.65
Other Financing Activities, net		 -11 -12 -11 -9.20 -11 -7.74 -6.10 -5.29 -7.79 -9.58 -14

Annual Balance Sheets for REGENXBIO

This table presents REGENXBIO's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 221 173 199 544 498 708 1,114 833 574 466 453
Total Current Assets		 118 93 168 338 345 531 519 416 335 278 281
Cash & Equivalents		 54 25 47 76 70 338 345 97 35 58 34
Short-Term Investments		 60 65 114 244 227 137 112 268 241 177 196
Accounts Receivable		 2.14 1.03 0.47 8.59 38 43 32 28 25 20 26
Prepaid Expenses		 1.02 1.78 5.33 5.73 6.48 11 19 14 15 9.07 12
Other Current Assets		 0.85 1.01 1.41 3.83 4.20 1.95 10 9.35 20 14 13
Plant, Property, & Equipment, net		 0.54 9.32 14 29 29 56 132 142 132 118 105
Total Noncurrent Assets		 103 70 17 177 124 121 464 276 107 70 67
Long-Term Investments		 103 69 16 151 104 47 392 201 39 10 11
Noncurrent Note & Lease Receivables		 - - - 23 4.16 3.27 2.26 1.50 0.70 0.47 2.31
Other Noncurrent Operating Assets		 0.17 0.40 0.86 2.32 15 69 67 72 65 58 52
Other Noncurrent Nonoperating Assets		 - 0.23 0.23 1.05 1.33 1.33 2.03 2.03 2.03 2.03 2.03
Total Liabilities & Shareholders' Equity		 221 173 199 544 498 708 1,114 833 574 466 453
Total Liabilities		 4.57 11 16 35 48 330 350 317 262 206 350
Total Current Liabilities		 4.34 9.67 14 22 34 81 130 130 130 103 118
Accounts Payable		 1.01 1.54 4.83 4.41 6.41 11 11 27 23 23 21
Accrued Expenses		 3.20 8.13 9.61 17 25 49 76 47 50 38 38
Current Deferred Revenue		 0.13 - - 0.60 0.00 0.45 3.33 1.83 0.15 0.12 10
Other Current Liabilities		 - - - - 2.42 21 40 55 58 42 48
Total Noncurrent Liabilities		 0.23 1.33 1.21 13 14 249 219 187 132 103 232
Noncurrent Deferred Revenue		 0.23 1.33 1.21 4.43 3.33 3.78 - - - 0.00 19
Other Noncurrent Operating Liabilities		 - - - 2.51 11 245 219 187 132 103 213
Total Equity & Noncontrolling Interests		 217 162 183 509 450 378 764 516 312 260 103
Total Preferred & Common Equity		 217 162 183 509 450 378 764 516 312 260 103
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 217 162 183 509 450 378 764 516 312 260 103
Common Stock		 269 276 372 593 628 667 928 973 1,021 1,193 1,229
Retained Earnings		 -52 -115 -188 -83 -178 -289 -161 -442 -705 -932 -1,126
Accumulated Other Comprehensive Income / (Loss)		 -0.72 -0.03 -0.72 -0.72 0.21 -0.36 -2.57 -15 -4.43 -0.74 -0.69

Quarterly Balance Sheets for REGENXBIO

This table presents REGENXBIO's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 884 748 682 634 629 569 519 491 581 525 342
Total Current Assets		 437 389 379 366 395 347 313 313 374 332 187
Cash & Equivalents		 119 70 69 53 113 58 57 130 80 59 15
Short-Term Investments		 264 262 251 249 226 233 199 138 244 215 135
Accounts Receivable		 33 19 21 28 16 23 24 18 20 25 10
Prepaid Expenses		 15 16 15 13 14 10 11 11 11 13 12
Other Current Assets		 6.85 23 22 23 27 23 23 16 19 19 14
Plant, Property, & Equipment, net		 141 142 139 136 128 124 121 114 111 108 102
Total Noncurrent Assets		 306 217 165 132 106 99 85 63 96 86 54
Long-Term Investments		 235 142 95 63 42 37 23 4.86 40 28 0.00
Noncurrent Note & Lease Receivables		 1.80 1.30 1.14 1.08 0.52 0.46 0.40 1.21 1.58 2.77 0.42
Other Noncurrent Operating Assets		 68 72 66 66 62 59 60 55 52 53 51
Other Noncurrent Nonoperating Assets		 2.03 2.03 2.26 2.26 2.03 2.03 2.03 2.03 2.03 2.03 2.03
Total Liabilities & Shareholders' Equity		 884 748 682 634 629 569 519 491 581 525 342
Total Liabilities		 320 283 277 271 239 221 218 217 367 364 321
Total Current Liabilities		 124 112 118 127 110 98 103 107 120 125 71
Accounts Payable		 25 23 12 22 31 16 20 19 22 22 21
Accrued Expenses		 44 32 51 46 33 42 49 24 36 38 22
Current Deferred Revenue		 5.90 1.31 0.45 0.44 0.01 0.02 0.14 14 14 13 5.92
Other Current Liabilities		 48 56 55 59 46 39 34 51 48 51 22
Total Noncurrent Liabilities		 196 170 159 143 128 123 115 110 248 239 250
Noncurrent Deferred Revenue		 - - - - - - - 26 24 21 23
Other Noncurrent Operating Liabilities		 196 170 159 143 128 123 115 84 224 218 227
Total Equity & Noncontrolling Interests		 564 465 406 363 391 348 301 274 214 161 21
Total Preferred & Common Equity		 564 465 406 363 391 348 301 274 214 161 21
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 564 465 406 363 391 348 301 274 214 161 21
Common Stock		 964 985 996 1,013 1,162 1,172 1,183 1,201 1,211 1,221 1,238
Retained Earnings		 -382 -508 -580 -642 -768 -821 -881 -926 -997 -1,059 -1,216
Accumulated Other Comprehensive Income / (Loss)		 -18 -12 -10 -7.41 -3.23 -2.27 -0.58 -0.76 -0.75 -0.65 -0.87

Annual Metrics And Ratios for REGENXBIO

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 26,313,471.00 26,475,379.00 31,145,292.00 35,840,359.00 36,874,282.00 37,408,448.00 42,949,562.00 - - - 50,623,086.00
DEI Adjusted Shares Outstanding		 26,313,471.00 26,475,379.00 31,145,292.00 35,840,359.00 36,874,282.00 37,408,448.00 42,949,562.00 - - - 50,623,086.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.90 -2.38 -2.35 2.79 -2.57 -2.97 2.98 - - - -3.83
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 23.99% -39.52% 126.48% 2,002.42% -83.88% 338.70% 204.30% -76.03% -19.94% -7.66% 104.54%
EBITDA Growth		 -517.76% -176.06% -13.68% 242.59% -237.64% 24.71% 266.97% -239.07% -2.12% 11.59% 31.71%
EBIT Growth		 -528.38% -182.40% -16.14% 227.89% -250.49% 21.28% 239.78% -263.37% -2.12% 13.03% 30.90%
NOPAT Growth		 -528.38% -182.40% -16.14% 259.20% -223.34% 19.98% 273.48% -227.09% -2.00% 12.97% 30.92%
Net Income Growth		 -469.85% -176.04% -16.20% 236.58% -194.79% -17.44% 214.91% -319.27% 6.00% 13.81% 14.63%
EPS Growth		 -42.31% 8.11% -2.94% 211.43% -194.51% -15.50% 197.65% -323.37% 7.38% 23.75% 18.08%
Operating Cash Flow Growth		 -838.52% -115.67% -19.43% 280.45% -202.92% 49.81% 504.87% -194.80% -5.26% 20.73% 28.40%
Free Cash Flow Firm Growth		 -1,083.19% -128.64% -18.36% 184.07% -329.83% 201.30% -23.12% -356.63% -6.48% 22.96% 122.20%
Invested Capital Growth		 102.99% 1,705.67% 151.77% 571.90% 13.47% -399.00% 40.41% 41.39% 91.35% 388.77% -1,198.80%
Revenue Q/Q Growth		 0.00% -37.43% 198.05% 17.27% -45.16% 6.68% 319.87% -75.56% -9.19% -1.18% 5.66%
EBITDA Q/Q Growth		 0.00% -30.11% 5.58% 38.03% -42.62% -14.39% 188.66% -286.16% -3.00% 4.97% -4.57%
EBIT Q/Q Growth		 0.00% -29.71% 4.85% 40.54% -41.04% -13.93% 175.60% -328.50% -2.43% 5.19% -4.09%
NOPAT Q/Q Growth		 0.00% -29.71% 4.85% 22.46% -40.27% -12.58% 199.80% -300.39% -2.34% 5.10% -4.05%
Net Income Q/Q Growth		 0.00% -29.73% 4.70% 25.50% -48.11% -21.62% 160.18% -480.68% -1.13% 4.90% -8.97%
EPS Q/Q Growth		 0.00% -263.01% 8.92% 19.21% -34.38% -20.65% 156.50% -477.91% -0.67% 8.57% -8.99%
Operating Cash Flow Q/Q Growth		 -25.54% -49.05% 10.21% 10.20% -24.75% 54.58% 363.22% -219.67% -0.64% 5.01% -20.01%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 10.91% -10.26% -4.20% 175.15% 62.21% -398.86% 0.27% 8.19% -27.13%
Invested Capital Q/Q Growth		 0.00% 152.43% 95.49% 127.31% -2.76% -217.34% -18.61% 7.57% -19.99% -38.73% 1.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 80.19% 79.10% 83.56% 95.57% 76.61% 71.93% 89.53% 51.61% 58.76% 65.72% 100.00%
EBITDA Margin		 -299.76% -1,368.32% -686.85% 46.58% -397.61% -68.24% 37.44% -217.27% -277.14% -265.34% -88.58%
Operating Margin		 -304.92% -1,423.84% -730.15% 40.32% -422.89% -77.14% 34.01% -233.20% -297.12% -280.03% -94.58%
EBIT Margin		 -304.92% -1,423.84% -730.15% 44.41% -414.52% -74.38% 34.17% -232.90% -297.09% -279.82% -94.53%
Profit (Net Income) Margin		 -300.62% -1,372.13% -704.02% 45.74% -268.88% -71.98% 27.18% -248.68% -291.99% -272.54% -113.75%
Tax Burden Percent		 100.00% 99.31% 100.00% 95.99% 97.17% 104.94% 90.51% 99.97% 99.94% 100.00% 100.00%
Interest Burden Percent		 98.59% 97.03% 96.42% 107.29% 66.75% 92.21% 87.90% 106.81% 98.34% 97.40% 120.34%
Effective Tax Rate		 0.00% 0.00% 0.00% 4.01% 0.00% 0.00% 9.49% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -3,404.39% -1,186.23% 341.82% -226.88% 0.00% 0.00% 0.00% 0.00% -3,918.02% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -3,395.22% -1,174.29% 337.03% -229.09% 0.00% 0.00% 0.00% 0.00% -3,895.37% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 3,371.12% 1,143.79% -312.93% 207.13% 0.00% 0.00% 0.00% 0.00% 3,838.53% 0.00%
Return on Equity (ROE)		 -21.61% -33.27% -42.45% 28.89% -19.76% -26.87% 22.39% -43.78% -63.65% -79.49% -107.00%
Cash Return on Invested Capital (CROIC)		 -14,933.26% -3,583.40% -1,272.52% 193.64% -239.50% 0.00% 0.00% 0.00% 0.00% -1,415.24% 0.00%
Operating Return on Assets (OROA)		 -20.58% -33.16% -40.86% 26.14% -28.04% -19.06% 17.64% -26.97% -38.10% -44.84% -35.06%
Return on Assets (ROA)		 -20.29% -31.95% -39.40% 26.92% -18.19% -18.45% 14.03% -28.79% -37.45% -43.68% -42.19%
Return on Common Equity (ROCE)		 -20.32% -33.27% -42.45% 28.89% -19.76% -26.87% 22.39% -43.78% -63.65% -79.49% -107.00%
Return on Equity Simple (ROE_SIMPLE)		 -10.52% -38.93% -39.98% 19.64% -21.04% -29.45% 16.73% -54.31% -84.52% -87.46% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -46 -53 85 -104 -83 145 -184 -188 -163 -113
NOPAT Margin		 -213.44% -996.69% -511.11% 38.70% -296.03% -54.00% 30.78% -163.24% -207.98% -196.02% -66.20%
Net Nonoperating Expense Percent (NNEP)		 -6.13% -9.17% -11.94% 4.79% 2.21% -6.01% -2.47% -13.58% -17.16% -22.65% -33.09%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -35.65% -60.21% -62.91% -109.84%
Cost of Revenue to Revenue		 19.81% 20.90% 16.44% 4.43% 23.39% 28.07% 10.47% 48.39% 41.24% 34.28% 0.00%
SG&A Expenses to Revenue		 156.98% 514.06% 261.99% 16.86% 147.06% 41.29% 16.87% 75.65% 98.06% 91.95% 48.62%
R&D to Revenue		 227.71% 991.11% 550.60% 38.38% 352.47% 107.59% 38.58% 215.09% 257.38% 250.24% 133.95%
Operating Expenses to Revenue		 385.11% 1,502.94% 813.71% 55.25% 499.50% 149.07% 55.51% 284.82% 355.88% 345.75% 194.58%
Earnings before Interest and Taxes (EBIT)		 -23 -65 -76 97 -146 -115 161 -263 -268 -233 -161
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -63 -71 102 -140 -105 176 -245 -250 -221 -151
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.01 3.04 5.66 2.95 3.36 4.49 1.83 1.90 2.53 1.48 7.10
Price to Tangible Book Value (P/TBV)		 2.01 3.04 5.66 2.95 3.36 4.49 1.83 1.90 2.53 1.48 7.10
Price to Revenue (P/Rev)		 57.57 107.02 99.64 6.88 42.88 10.98 2.97 8.71 8.75 4.60 4.28
Price to Earnings (P/E)		 0.00 0.00 0.00 15.04 0.00 0.00 10.94 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 6.65% 0.00% 0.00% 9.14% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1,561.25 130.46 134.04 24.12 22.73 0.00 0.00 0.00 0.00 10.83 0.00
Enterprise Value to Revenue (EV/Rev)		 29.01 72.38 82.67 4.75 31.53 7.60 1.17 3.70 5.27 1.66 2.86
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 10.21 0.00 0.00 3.12 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 10.70 0.00 0.00 3.42 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 12.28 0.00 0.00 3.79 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 9.93 0.00 0.00 2.51 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 21.68 0.00 10.53 6.41 0.00 0.00 0.00 12.18
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -0.99 -0.97 -0.93 -0.90 -1.12 -1.20 -1.11 -1.07 -0.99 -1.35
Leverage Ratio		 1.07 1.04 1.08 1.07 1.09 1.46 1.60 1.52 1.70 1.82 2.54
Compound Leverage Factor		 1.05 1.01 1.04 1.15 0.73 1.34 1.40 1.62 1.67 1.77 3.05
Debt to Total Capital		 0.00% 0.00% 0.00% 1.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 98.86% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -4.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -5.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 57.30 25.23 38.10 27.27 18.35 2.95 3.51 0.62 -0.87 -2.71 -2.60
Noncontrolling Interest Sharing Ratio		 5.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 27.23 9.66 11.64 15.24 10.25 6.52 3.98 3.19 2.57 2.69 2.38
Quick Ratio		 26.80 9.37 11.17 14.81 9.93 6.37 3.75 3.01 2.30 2.47 2.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -21 -48 -57 48 -110 112 86 -220 -234 -181 40
Operating Cash Flow to CapEx		 -4,313.22% -595.88% -809.94% 788.13% -918.98% -201.20% 260.02% -675.33% -2,192.84% -7,106.94% -5,135.17%
Free Cash Flow to Firm to Interest Expense		 -1,052.80 0.00 0.00 0.00 0.00 144.66 3.26 -9.46 -34.15 -14.26 0.89
Operating Cash Flow to Interest Expense		 -1,125.75 0.00 0.00 0.00 0.00 -70.12 8.33 -8.92 -31.83 -13.68 -2.75
Operating Cash Flow Less CapEx to Interest Expense		 -1,151.85 0.00 0.00 0.00 0.00 -104.97 5.13 -10.24 -33.28 -13.87 -2.81
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.02 0.06 0.59 0.07 0.26 0.52 0.12 0.13 0.16 0.37
Accounts Receivable Turnover		 3.78 2.90 13.81 48.24 1.51 3.81 12.47 3.73 3.41 3.68 7.28
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.93 0.89 10.24 1.22 3.62 5.00 0.83 0.66 0.67 1.53
Accounts Payable Turnover		 1.08 0.75 0.54 2.09 1.52 5.10 4.48 2.83 1.49 1.25 0.00
Days Sales Outstanding (DSO)		 96.64 125.99 26.43 7.57 242.08 95.81 29.27 97.98 106.93 99.13 50.17
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 336.47 486.60 680.77 174.24 239.64 71.63 81.53 129.15 245.21 291.21 0.00
Cash Conversion Cycle (CCC)		 -239.83 -360.62 -654.34 -166.68 2.44 24.18 -52.26 -31.17 -138.28 -192.08 50.17
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.14 2.55 6.41 43 49 -146 -87 -51 -4.42 13 -140
Invested Capital Turnover		 -3.32 3.42 2.32 8.83 0.77 -3.18 -4.03 -1.63 -3.25 19.99 -2.68
Increase / (Decrease) in Invested Capital		 4.86 2.41 3.86 37 5.80 -195 59 36 47 17 -153
Enterprise Value (EV)		 220 332 859 1,039 1,111 1,174 549 417 476 138 488
Market Capitalization		 437 491 1,036 1,504 1,511 1,697 1,399 982 790 383 729
Book Value per Share		 $8.24 $6.11 $5.88 $14.20 $12.21 $10.10 $17.87 $11.92 $7.09 $5.24 $2.03
Tangible Book Value per Share		 $8.24 $6.11 $5.88 $14.20 $12.21 $10.10 $17.87 $11.92 $7.09 $5.24 $2.03
Total Capital		 217 162 183 515 450 378 764 516 312 260 103
Total Debt		 0.00 0.00 0.00 5.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 5.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -217 -159 -176 -465 -400 -523 -849 -565 -314 -245 -241
Capital Expenditures (CapEx)		 0.52 8.15 7.16 13 12 27 84 31 9.96 2.44 2.41
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.33 -5.85 -7.22 -4.02 15 -26 -69 -79 -71 -60 -67
Debt-free Net Working Capital (DFNWC)		 114 84 154 316 311 450 388 286 205 175 163
Net Working Capital (NWC)		 114 84 154 316 311 450 388 286 205 175 163
Net Nonoperating Expense (NNE)		 6.62 17 20 -15 -9.57 28 17 96 76 64 81
Net Nonoperating Obligations (NNO)		 -217 -159 -177 -466 -401 -524 -851 -567 -316 -247 -243
Total Depreciation and Amortization (D&A)		 0.39 2.55 4.50 4.74 5.96 9.49 15 18 18 12 10
Debt-free, Cash-free Net Working Capital to Revenue		 -4.38% -127.52% -69.45% -1.84% 42.99% -16.81% -14.69% -70.17% -78.19% -71.86% -39.24%
Debt-free Net Working Capital to Revenue		 1,499.86% 1,823.97% 1,477.53% 144.50% 883.71% 290.97% 82.57% 253.31% 226.83% 209.78% 95.74%
Net Working Capital to Revenue		 1,499.86% 1,823.97% 1,477.53% 144.50% 883.71% 290.97% 82.57% 253.31% 226.83% 209.78% 95.74%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.59) ($2.38) ($2.45) $2.99 ($2.58) ($2.98) $3.01 ($6.50) ($6.02) ($4.59) ($3.76)
Adjusted Weighted Average Basic Shares Outstanding		 26.33M 26.51M 31.66M 33.43M 36.69M 37.28M 42.44M 43.15M 43.73M 49.51M 51.57M
Adjusted Diluted Earnings per Share		 ($2.59) ($2.38) ($2.45) $2.73 ($2.58) ($2.98) $2.91 ($6.50) ($6.02) ($4.59) ($3.76)
Adjusted Weighted Average Diluted Shares Outstanding		 26.33M 26.51M 31.66M 36.65M 36.69M 37.28M 43.91M 43.15M 43.73M 49.51M 51.57M
Adjusted Basic & Diluted Earnings per Share		 ($2.59) ($2.38) ($2.45) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.17M 26.41M 29.88M 36.42M 37.14M 42.50M 42.95M 43.46M 44.43M 50.09M 51.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -46 -53 85 -104 -83 145 -184 -188 -162 -113
Normalized NOPAT Margin		 -213.44% -996.69% -511.11% 38.70% -296.03% -54.00% 30.78% -163.24% -207.98% -194.26% -66.20%
Pre Tax Income Margin		 -300.62% -1,381.61% -704.02% 47.65% -276.70% -68.59% 30.03% -248.75% -292.15% -272.54% -113.75%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1,156.85 0.00 0.00 0.00 0.00 -149.11 6.12 -11.29 -39.07 -18.42 -3.58
NOPAT to Interest Expense		 -809.80 0.00 0.00 0.00 0.00 -108.25 5.51 -7.91 -27.35 -12.90 -2.51
EBIT Less CapEx to Interest Expense		 -1,182.95 0.00 0.00 0.00 0.00 -183.96 2.91 -12.61 -40.52 -18.61 -3.63
NOPAT Less CapEx to Interest Expense		 -835.90 0.00 0.00 0.00 0.00 -143.10 2.31 -9.23 -28.80 -13.10 -2.56
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.10% -0.61% 0.62% 0.00% 0.00% 0.30% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for REGENXBIO

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 50,086,138.00 50,160,352.00 50,514,216.00 50,623,086.00 51,612,984.00
DEI Adjusted Shares Outstanding		 - - - - - - 50,086,138.00 50,160,352.00 50,514,216.00 50,623,086.00 51,612,984.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - 0.12 -1.41 -1.23 -1.33 -1.74
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9.06% -29.13% -18.37% 11.60% -16.31% -4.50% 469.79% -4.20% 22.88% 43.00% -92.82%
EBITDA Growth		 8.56% -13.83% 1.82% 22.05% 2.07% 19.30% 125.01% -14.11% 15.28% -13.64% -634.50%
EBIT Growth		 8.62% -11.01% 3.42% 23.35% 4.39% 19.92% 119.04% -12.94% 15.57% -12.35% -785.86%
NOPAT Growth		 8.57% -10.61% 3.47% 23.35% 4.44% 19.62% 127.13% -12.92% 15.57% -12.20% -581.19%
Net Income Growth		 18.04% -4.93% 5.02% 26.47% 3.67% 18.61% 109.61% -33.75% -3.93% -31.19% -1,580.37%
EPS Growth		 19.43% -2.90% 9.80% 36.75% 17.02% 30.28% 108.70% -31.43% -2.56% -31.31% -1,533.33%
Operating Cash Flow Growth		 2.08% -3.53% 31.47% 3.86% 17.93% 22.41% 160.64% -8.45% -38.01% -65.35% -326.55%
Free Cash Flow Firm Growth		 -42.81% -19.44% 44.05% -862.71% 29.95% 41.84% 132.91% 280.98% 286.53% 311.86% 248.46%
Invested Capital Growth		 93.33% 91.35% 178.01% 260.70% 665.55% 388.77% -106.89% -902.37% -785.09% -1,198.80% -23,371.25%
Revenue Q/Q Growth		 44.74% -23.18% -29.67% 42.72% 8.53% -12.33% 319.59% -76.00% 39.21% 2.03% -78.93%
EBITDA Q/Q Growth		 11.12% 1.18% -0.27% 11.50% -11.67% 18.56% 131.08% -503.75% 17.10% -9.24% -46.18%
EBIT Q/Q Growth		 11.17% 1.33% 0.34% 12.25% -10.79% 17.35% 123.70% -620.55% 17.18% -9.97% -44.65%
NOPAT Q/Q Growth		 11.15% 1.63% 0.06% 12.25% -10.78% 17.25% 133.73% -465.26% 17.17% -9.97% -44.64%
Net Income Q/Q Growth		 14.15% -1.65% -0.70% 16.33% -12.47% 14.11% 111.88% -1,265.07% 12.60% -8.41% -34.11%
EPS Q/Q Growth		 15.06% -0.71% 2.82% 23.91% -11.43% 15.38% 112.12% -1,250.00% 13.04% -8.33% -32.31%
Operating Cash Flow Q/Q Growth		 -4.41% 17.50% -36.05% 17.96% 10.88% 22.01% 206.34% -246.72% -13.41% 6.56% -45.70%
Free Cash Flow Firm Q/Q Growth		 -1,235.18% 5.83% 30.77% -10.59% 2.85% 21.81% 139.17% 508.21% 0.13% -11.19% -35.57%
Invested Capital Q/Q Growth		 68.76% -19.99% 283.97% 133.04% 9.93% -38.73% -104.39% -27,033.04% 6.14% 1.73% 6.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 57.16% 49.41% 72.58% 52.55% 48.81% 93.79% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -209.81% -269.89% -384.80% -238.62% -245.52% -228.05% 16.89% -284.23% -169.27% -181.22% -1,257.13%
Operating Margin		 -224.67% -287.68% -408.80% -251.34% -256.55% -242.14% 13.62% -296.26% -176.27% -189.99% -1,303.96%
EBIT Margin		 -224.47% -288.32% -408.56% -251.21% -256.45% -241.75% 13.65% -296.16% -176.21% -189.93% -1,303.71%
Profit (Net Income) Margin		 -213.97% -283.12% -405.39% -237.67% -246.30% -241.28% 6.83% -331.81% -208.32% -221.34% -1,408.59%
Tax Burden Percent		 100.00% 99.76% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.32% 98.43% 99.22% 94.61% 96.04% 99.81% 50.06% 112.04% 118.23% 116.54% 108.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -4,380.38% -1,767.41% -3,387.87% 564.40% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -4,376.70% -1,762.42% -3,382.46% 566.24% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 4,335.18% 1,716.97% 3,333.11% -559.80% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -56.22% -63.65% -60.80% -45.20% -50.44% -54.77% 4.60% -62.49% -76.88% -107.00% -196.43%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -2,518.17% -1,081.77% -944.45% -1,415.24% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -29.40% -36.98% -51.46% -35.74% -37.52% -38.74% 3.82% -80.21% -54.44% -70.45% -274.95%
Return on Assets (ROA)		 -28.02% -36.31% -51.06% -33.81% -36.03% -38.67% 1.91% -89.86% -64.36% -82.10% -297.07%
Return on Common Equity (ROCE)		 -56.22% -63.65% -60.80% -45.20% -50.44% -54.77% 4.60% -62.49% -76.88% -107.00% -196.43%
Return on Equity Simple (ROE_SIMPLE)		 -71.75% 0.00% -66.59% -69.22% -79.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -45 -45 -45 -39 -43 -36 12 -44 -37 -40 -58
NOPAT Margin		 -157.27% -201.38% -286.16% -175.94% -179.59% -169.50% 13.62% -207.38% -123.39% -132.99% -912.77%
Net Nonoperating Expense Percent (NNEP)		 -3.33% -4.11% -4.34% -3.69% -4.99% -5.41% -1.84% -7.65% -8.64% -10.95% -14.84%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.35% - - - -13.85% 4.42% -20.73% -22.72% -39.27% -276.79%
Cost of Revenue to Revenue		 42.84% 50.59% 27.42% 47.45% 51.19% 6.21% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 79.83% 85.89% 117.08% 84.57% 80.27% 94.52% 22.86% 93.09% 68.12% 73.77% 333.27%
R&D to Revenue		 201.23% 250.67% 351.07% 219.19% 224.94% 237.48% 59.64% 278.57% 188.68% 196.50% 896.90%
Operating Expenses to Revenue		 281.82% 337.09% 481.39% 303.89% 305.36% 335.93% 86.38% 396.26% 276.27% 289.99% 1,403.96%
Earnings before Interest and Taxes (EBIT)		 -65 -64 -64 -56 -62 -51 12 -63 -52 -58 -83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -60 -60 -53 -59 -48 15 -61 -50 -55 -80
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.99 2.53 2.37 1.65 1.72 1.48 1.31 1.93 3.02 7.10 20.52
Price to Tangible Book Value (P/TBV)		 1.99 2.53 2.37 1.65 1.72 1.48 1.31 1.93 3.02 7.10 20.52
Price to Revenue (P/Rev)		 7.28 8.75 10.69 6.47 6.15 4.60 2.29 2.64 3.02 4.28 4.92
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 67.24 13.15 11.52 10.83 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.61 5.27 6.30 2.80 2.84 1.66 0.54 0.31 1.15 2.86 3.21
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.87 3.37 12.18 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.06 -1.07 -1.00 -0.99 -0.97 -0.99 -0.99 -1.24 -1.26 -1.35 -1.45
Leverage Ratio		 1.64 1.70 1.61 1.66 1.73 1.82 1.68 2.05 2.26 2.54 2.82
Compound Leverage Factor		 1.56 1.67 1.60 1.57 1.67 1.82 0.84 2.29 2.67 2.96 3.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.46 0.30 0.97 -0.10 -0.69 -1.42 -0.74 -1.30 -1.57 -1.84 -4.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.87 2.57 3.59 3.53 3.05 2.69 2.93 3.13 2.66 2.38 2.62
Quick Ratio		 2.59 2.30 3.22 3.19 2.72 2.47 2.68 2.87 2.40 2.17 2.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -97 -91 -63 -70 -68 -53 21 127 127 113 73
Operating Cash Flow to CapEx		 -3,433.43% -3,619.89% -9,956.01% -9,598.52% -12,438.34% -2,930.86% 3,284.08% -12,619.44% -11,397.15% -10,293.31% -6,168.91%
Free Cash Flow to Firm to Interest Expense		 -59.73 -67.02 -32.06 -155.78 -82.87 -5.64 2.43 11.52 9.63 9.17 8.33
Operating Cash Flow to Interest Expense		 -30.42 -29.90 -28.11 -101.33 -49.45 -3.36 3.92 -4.49 -4.25 -4.26 -8.75
Operating Cash Flow Less CapEx to Interest Expense		 -31.31 -30.73 -28.39 -102.39 -49.85 -3.47 3.80 -4.52 -4.29 -4.30 -8.89
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.13 0.13 0.14 0.15 0.16 0.28 0.27 0.31 0.37 0.21
Accounts Receivable Turnover		 3.28 3.41 5.00 4.03 3.27 3.68 9.21 7.24 6.59 7.28 6.22
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.72 0.66 0.64 0.68 0.66 0.67 1.29 1.33 1.41 1.53 0.81
Accounts Payable Turnover		 1.65 1.49 1.37 2.75 1.86 1.25 0.00 1.50 1.37 0.00 0.00
Days Sales Outstanding (DSO)		 111.28 106.93 73.00 90.57 111.77 99.13 39.62 50.38 55.38 50.17 58.66
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 221.63 245.21 266.73 132.77 196.22 291.21 0.00 242.87 266.96 0.00 0.00
Cash Conversion Cycle (CCC)		 -110.36 -138.28 -193.74 -42.21 -84.45 -192.08 39.62 -192.49 -211.58 50.17 58.66
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.68 -4.42 8.13 19 21 13 -0.56 -152 -143 -140 -131
Invested Capital Turnover		 -3.37 -3.25 -75.71 24.90 9.84 19.99 41.43 -2.34 -2.65 -2.68 -1.33
Increase / (Decrease) in Invested Capital		 52 47 19 31 24 17 -8.69 -171 -163 -153 -131
Enterprise Value (EV)		 359 476 546 249 240 138 85 48 185 488 282
Market Capitalization		 724 790 927 576 518 383 358 412 487 729 433
Book Value per Share		 $8.26 $7.09 $8.54 $7.07 $6.10 $5.24 $5.47 $4.26 $3.20 $2.03 $0.41
Tangible Book Value per Share		 $8.26 $7.09 $8.54 $7.07 $6.10 $5.24 $5.47 $4.26 $3.20 $2.03 $0.41
Total Capital		 363 312 391 348 301 260 274 214 161 103 21
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -365 -314 -381 -327 -279 -245 -273 -364 -302 -241 -150
Capital Expenditures (CapEx)		 1.44 1.13 0.56 0.47 0.33 1.08 1.02 0.39 0.49 0.51 1.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -63 -71 -53 -42 -45 -60 -61 -69 -67 -67 -35
Debt-free Net Working Capital (DFNWC)		 238 205 285 248 211 175 207 254 207 163 115
Net Working Capital (NWC)		 238 205 285 248 211 175 207 254 207 163 115
Net Nonoperating Expense (NNE)		 16 18 19 14 16 15 6.04 27 25 27 32
Net Nonoperating Obligations (NNO)		 -367 -316 -383 -329 -281 -247 -275 -366 -304 -243 -153
Total Depreciation and Amortization (D&A)		 4.24 4.09 3.71 2.81 2.65 2.91 2.88 2.55 2.06 2.64 2.98
Debt-free, Cash-free Net Working Capital to Revenue		 -63.79% -78.19% -61.65% -47.11% -53.11% -71.86% -39.16% -44.35% -41.41% -39.24% -39.95%
Debt-free Net Working Capital to Revenue		 239.99% 226.83% 328.90% 278.97% 249.83% 209.78% 131.77% 163.18% 128.57% 95.74% 131.41%
Net Working Capital to Revenue		 239.99% 226.83% 328.90% 278.97% 249.83% 209.78% 131.77% 163.18% 128.57% 95.74% 131.41%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99) $0.12 ($1.38) ($1.20) ($1.30) ($1.72)
Adjusted Weighted Average Basic Shares Outstanding		 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M 51.36M 51.48M 51.69M 51.57M 52.43M
Adjusted Diluted Earnings per Share		 ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99) $0.12 ($1.38) ($1.20) ($1.30) ($1.72)
Adjusted Weighted Average Diluted Shares Outstanding		 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M 51.43M 51.48M 51.69M 51.57M 52.43M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.99M 44.43M 49.26M 49.42M 49.55M 50.09M 50.16M 50.51M 50.62M 51.61M 51.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -45 -45 -43 -39 -43 -36 8.49 -44 -37 -40 -58
Normalized NOPAT Margin		 -157.27% -201.38% -276.75% -175.94% -179.59% -169.50% 9.54% -207.38% -123.39% -132.99% -912.77%
Pre Tax Income Margin		 -213.97% -283.80% -405.39% -237.67% -246.30% -241.28% 6.83% -331.81% -208.32% -221.34% -1,408.59%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -39.97 -46.99 -32.35 -124.74 -75.67 -5.45 1.42 -5.75 -3.98 -4.69 -9.57
NOPAT to Interest Expense		 -28.00 -32.82 -22.66 -87.36 -52.99 -3.82 1.42 -4.03 -2.79 -3.29 -6.70
EBIT Less CapEx to Interest Expense		 -40.85 -47.81 -32.63 -125.80 -76.07 -5.56 1.30 -5.79 -4.02 -4.73 -9.71
NOPAT Less CapEx to Interest Expense		 -28.89 -33.65 -22.94 -88.42 -53.39 -3.93 1.30 -4.06 -2.82 -3.33 -6.84
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

REGENXBIO’s latest quarter shows a business with strong liquidity, but also heavy operating losses and ongoing cash burn. In Q1 2026, the company generated just $6.4 million of revenue while posting a net loss of $90.1 million. That’s a sharp reminder that this remains a pre-profit biotech company, where the investment case depends heavily on pipeline progress and future commercialization, not current earnings.

One of the biggest positives is the balance sheet. As of March 31, 2026, REGENXBIO had $15.2 million in cash and $135.3 million in short-term investments, for total current assets of $186.5 million. Including long-term assets, total assets were $341.9 million. That gives the company meaningful flexibility, even though losses are large.

However, cash is still being consumed quickly. Operating cash flow was negative $76.2 million in Q1 2026, and net change in cash and equivalents was negative $19.2 million after investment activity and financing items. The company is clearly still reliant on its cash pile and investment portfolio to fund operations.

Revenue declined sharply sequentially and remains volatile. Revenue fell from $30.3 million in Q4 2025 to $6.4 million in Q1 2026. That kind of quarter-to-quarter swing is common in biotech, but it also highlights how lumpy REGENXBIO’s revenue base is.

Operating losses remain substantial. Total operating expenses in Q1 2026 were $89.8 million, driven mainly by $57.3 million in R&D and $21.3 million in SG&A. The company’s operating loss of $83.4 million shows that spending remains high relative to sales.

Compared with the prior year, revenue is down and losses are worse. In Q1 2025, revenue was $89.0 million and net income was a positive $6.1 million, helped by a much stronger operating result and favorable financing/investing dynamics. By contrast, Q1 2026 moved back into a much deeper loss, indicating a deterioration in the quarterly income profile.

  • Strong liquidity cushion: $186.5 million in current assets, backed by cash and short-term investments.
  • Low immediate debt pressure: the company’s balance sheet shows no obvious near-term liquidity crisis from these statements alone.
  • Investments provide flexibility: the portfolio of short-term investments can help fund operations while the pipeline develops.
  • Revenue is highly variable: quarterly sales can swing materially, making year-over-year comparisons noisy.
  • Large non-cash adjustments: depreciation and other non-cash items materially affect cash flow reconciliation.
  • Deferred revenue remains present: current and noncurrent deferred revenue suggest some prepayments or collaboration-related support.
  • Net loss widened sharply: Q1 2026 net loss of $90.1 million versus a $67.1 million loss in Q4 2025.
  • Operating cash burn is heavy: negative $76.2 million in operating cash flow in the quarter.
  • R&D spending remains very high: necessary for a biotech, but it keeps losses elevated.
  • Equity cushion is thin: total common equity was only $21.1 million, down from $161.5 million a year earlier.

Bottom line: REGENXBIO’s financial position is still supported by a sizable investment portfolio, but the company is burning cash and posting large losses. For retail investors, the key question is whether upcoming clinical, regulatory, or commercial milestones can justify the continued spending and eventually turn that liquidity into value creation.

07/16/26 08:51 PM ETAI Generated. May Contain Errors.

REGENXBIO Financials - Frequently Asked Questions

According to the most recent income statement we have on file, REGENXBIO's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

REGENXBIO's net income appears to be on an upward trend, with a most recent value of -$193.88 million in 2025, rising from -$22.81 million in 2015. The previous period was -$227.10 million in 2024. See REGENXBIO's forecast for analyst expectations on what's next for the company.

REGENXBIO's total operating income in 2025 was -$161.20 million, based on the following breakdown:
  • Total Gross Profit: $170.44 million
  • Total Operating Expenses: $331.64 million

Over the last 10 years, REGENXBIO's total revenue changed from $7.59 million in 2015 to $170.44 million in 2025, a change of 2,146.2%.

REGENXBIO's total liabilities were at $350.30 million at the end of 2025, a 69.8% increase from 2024, and a 7,561.8% increase since 2015.

In the past 10 years, REGENXBIO's cash and equivalents has ranged from $24.84 million in 2016 to $345.21 million in 2021, and is currently $34.47 million as of their latest financial filing in 2025.

Over the last 10 years, REGENXBIO's book value per share changed from 8.24 in 2015 to 2.03 in 2025, a change of -75.4%.


Related Companies

Financial statements for NASDAQ:RGNX last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The Lithium Gold Rush Minted A New $1B Unicorn
The Lithium Gold Rush Minted A New $1B Unicorn This lithium producer surpassed a $1B private valuation, joi...
EnergyX | Sponsoredtc pixel
What Saudi Arabia just did to the dollar changes everything
In June 2024, a 50-year arrangement tying Saudi oil to the U.S. dollar quietly expired. Garrett Goggin, CFA, C...
Golden Portfolio | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel